|
|
||||||||
The Journal of Immunology, Vol 159, Issue 11 5226-5232, Copyright © 1997 by American Association of Immunologists
ARTICLES |
S Inoue, K Kontani, N Tsujimoto, Y Kanda, N Hosoda, S Hoshino, O Hazeki and T Katada
Department of Physiological Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan.
The human surface Ag CD38 is a 46-kDa type II transmembrane glycoprotein, and its expression is dependent on the cell differentiation and activation of lymphocytes. Our previous work in human myeloid cells showed that ligation of CD38 with mAbs (HB-7 and T- 16; IgG1 subclass) not only induced protein-tyrosine phosphorylation but also potentiated superoxide generation stimulated by G protein- coupled receptors. In the present study we analyzed the mechanisms of action of the agonistic mAbs. HB-7-induced tyrosine phosphorylation could be still observed in human myeloid cells expressing CD38 mutants, of which cytoplasmic and transmembrane domains had been deleted or replaced by those of another type II glycoprotein (PC-1). Moreover, N- linked glycosylation on the cell surface CD38 was not required for the HB-7-induced cell signaling. The profile of tyrosine-phosphorylated proteins by HB-7 was exactly the same as that induced by cross-linking of FcgammaII receptors (FcgammaRII/CD32), and FcgammaRII itself was tyrosine phosphorylated in the two stimulated cells. The HB-7-induced tyrosine phosphorylation was completely abolished after masking of FcgammaRII with its mAb. Finally, F(ab')2 of HB-7 failed to mimic the actions of the whole form of mAb. These results indicate that anti-CD38 mAb-induced tyrosine phosphorylation and its associated cell response are entirely mediated through the FcgammaRII-induced signaling pathway, possibly resulting from stimulation of the cell surface human FcgammaRII with the mouse Fc region (IgG1 subclass) of CD38-ligated mAbs.
This article has been cited by other articles:
![]() |
F. Malavasi, S. Deaglio, A. Funaro, E. Ferrero, A. L. Horenstein, E. Ortolan, T. Vaisitti, and S. Aydin Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology Physiol Rev, July 1, 2008; 88(3): 841 - 886. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Momose, H. Kurosu, N. Tsujimoto, K. Kontani, K. Tsujita, H. Nishina, and T. Katada Dual Phosphorylation of Phosphoinositide 3-Kinase Adaptor Grb2-Associated Binder 2 Is Responsible for Superoxide Formation Synergistically Stimulated by Fc{gamma} and Formyl-Methionyl-Leucyl-Phenylalanine Receptors in Differentiated THP-1 Cells J. Immunol., October 15, 2003; 171(8): 4227 - 4234. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Musso, S. Deaglio, L. Franco, L. Calosso, R. Badolato, G. Garbarino, U. Dianzani, and F. Malavasi CD38 expression and functional activities are up-regulated by IFN-{gamma} on human monocytes and monocytic cell lines J. Leukoc. Biol., April 1, 2001; 69(4): 605 - 612. [Abstract] [Full Text] |
||||
![]() |
Y.-S. Cho, M.-K. Han, Y. B. Choi, Y. Yun, J. Shin, and U.-H. Kim Direct Interaction of the CD38 Cytoplasmic Tail and the Lck SH2 Domain. CD38 TRANSDUCES T CELL ACTIVATION SIGNALS THROUGH ASSOCIATED Lck J. Biol. Chem., January 21, 2000; 275(3): 1685 - 1690. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Todisco, T. Suzuki, K. Srivannaboon, E. Coustan-Smith, S. C. Raimondi, F. G. Behm, A. Kitanaka, and D. Campana CD38 ligation inhibits normal and leukemic myelopoiesis Blood, January 15, 2000; 95(2): 535 - 542. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kitanaka, T. Suzuki, C. Ito, H. Nishigaki, E. Coustan-Smith, T. Tanaka, Y. Kubota, and D. Campana CD38-Mediated Signaling Events in Murine Pro-B Cells Expressing Human CD38 With or Without Its Cytoplasmic Domain J. Immunol., February 15, 1999; 162(4): 1952 - 1958. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-T. Zilber, S. Gregory, R. Mallone, S. Deaglio, F. Malavasi, D. Charron, and C. Gelin CD38 expressed on human monocytes: A coaccessory molecule in the superantigen-induced proliferation PNAS, March 14, 2000; 97(6): 2840 - 2845. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |